SCHEMBL2931417

SCHEMBL2931417

COC(=O)c1c(SCc2ccccc2)ccc2nc(Nc3cccc(Cl)c3Cl)[nH]c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
METAP2 P50579 2/20 0.38
P2RX7 Q99572 1/20 0.38
LMNA P02545 2/20 0.37
NPC1 O15118 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX5 P09917 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
PLA2G2A P14555 1/20 0.36
PKM P14618 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TP53 P04637 2/20 0.35
PRMT5 O14744 2/20 0.34
WDR77 Q9BQA1 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925046 0.91 MAPT (0.39) MAPTMETAP2P2RX7LMNASMN1; SMN2
SCHEMBL13176992 0.82 LMNA (0.38) MAPTMETAP2LMNA
SCHEMBL2925195 0.81 NPC1 (0.40) MAPTP2RX7NPC1RAB9AALOX5
SCHEMBL2931594 0.79 RXFP1 (0.44) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2924883 0.78 MAPT (0.44) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL1115889 0.75 MAPT (0.43) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2927954 0.73 MAPT (0.39) MAPTP2RX7NPC1RAB9ASMN1; SMN2
SCHEMBL1115901 0.73 MAPT (0.44) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL1115893 0.72 MAPT (0.42) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2932570 0.71 MAPT (0.42) MAPTLMNARAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 MAPT 2716/4885METAP2 3581/4885P2RX7 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.